OS Therapies, Inc. (OSTX)
1.00
+0.02
(+2.03%)
USD |
NYAM |
Nov 06, 16:00
0.9355
-0.06
(-6.45%)
After-Hours: 20:00
OS Therapies Net Income (Quarterly) : -8.632M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.632M |
| March 31, 2026 | -10.40M |
| December 31, 2025 | -13.46M |
| September 30, 2025 | -6.880M |
| June 30, 2025 | -4.537M |
| March 31, 2025 | -3.877M |
| December 31, 2024 | -2.991M |
| September 30, 2024 | -2.875M |
| June 30, 2024 | -1.558M |
| Date | Value |
|---|---|
| March 31, 2024 | -1.459M |
| December 31, 2023 | -1.465M |
| September 30, 2023 | -1.975M |
| June 30, 2023 | -2.505M |
| March 31, 2023 | -1.847M |
| December 31, 2022 | -2.552M |
| March 31, 2022 | -1.362M |
| December 31, 2021 | -1.665B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 14.16M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 8.632M |
| EPS Diluted (Quarterly) | -0.1966 |
| Enterprise Value | 46.15M |
| Earnings Yield | -104.3% |
| Normalized Earnings Yield | -104.34 |